KRAS and neoplasm: These parameters were patient age (p = 0.048), tumor localization (p < 0.001), higher M status (p = 0.047), molecular subtype (p = 0.003), especially the MSI status (p = 0.001), mutations in K-Ras (p = 0.019), and B-Raf (p = 0.002) as well as a significantly better engraftment of metastatic (p = 0.014) tissues.